Page 46 - 84_02
P. 46
Differentiation therapy: development of a new drug discovery platform
promoter enables breast cancer cell plasticity and 48. Horton SJ, Huntly BJ. Recent advances in acute
enhances tumorigenicity. Cell. 2013 Jul 03;154(1):61- myeloid leukemia stem cell biology. Haematologica.
74. 2012 Jul;97(7):966-74.
35. Vermeulen L, De Sousa EMF, van der Heijden M, 49. Felipe Rico J, Hassane DC, Guzman ML. Acute
Cameron K, de Jong JH, Borovski T, et al. Wnt myelogenous leukemia stem cells: from Bench to
activity defines colon cancer stem cells and is Bedside. Cancer Lett. 2013 Sep 10;338(1):4-9.
regulated by the microenvironment. Nat Cell Biol.
2010 May;12(5):468-76. 50. Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao
MP, Majeti R, et al. CD47 is upregulated on
36. Notta F, Mullighan CG, Wang JCY, Poeppl A, circulating hematopoietic stem cells and leukemia
Doulatov S, Phillips LA, et al. Evolution of human cells to avoid phagocytosis. Cell. 2009 Jul
BCR-ABL1 lymphoblastic leukaemia-initiating cells. 23;138(2):271-85.
Nature. 2011;469(7330):362-7.
51. Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal
37. Kreso A, O'Brien CA, van Galen P, Gan OI, Notta F, S, Gibbs KD, Jr., et al. CD47 is an adverse prognostic
Brown AMK, et al. Variable clonal repopulation factor and therapeutic antibody target on human acute
dynamics influence chemotherapy response in myeloid leukemia stem cells. Cell. 2009 Jul
colorectal cancer. Science (New York, N Y ). 23;138(2):286-99.
2013;339(6119):543-8.
52. Gentles AJ, Plevritis SK, Majeti R, Alizadeh AA.
38. van Delft FW, Horsley S, Colman S, Anderson K, Association of a leukemic stem cell gene expression
Bateman C, Kempski H, et al. Clonal origins of signature with clinical outcomes in acute myeloid
relapse in ETV6-RUNX1 acute lymphoblastic leukemia. JAMA. 2010 Dec 22;304(24):2706-15.
leukemia. Blood. 2011;117(23):6247-54.
53. Eppert K, Takenaka K, Lechman ER, Waldron L,
39. Perl AE, Carroll M. Exploiting signal transduction Nilsson B, van Galen P, et al. Stem cell gene
pathways in acute myelogenous leukemia. Curr Treat expression programs influence clinical outcome in
Options Oncol. 2007 Aug;8(4):265-76. human leukemia. Nat Med. 2011 Sep;17(9):1086-93.
40. Lowenberg B, Downing JR, Burnett A. Acute myeloid 54. de Jonge DM, Jones A, Phillips R, Chung M.
leukemia. N Engl J Med. 1999 Sep 30;341(14):1051- Understanding the essence of home: older people's
62. experience of home in Australia. Occup Ther Int. 2011
Mar;18(1):39-47.
41. Dohner H, Estey EH, Amadori S, Appelbaum FR,
Buchner T, Burnett AK, et al. Diagnosis and 55. Lane SW, Scadden DT, Gilliland DG. The leukemic
management of acute myeloid leukemia in adults: stem cell niche: current concepts and therapeutic
recommendations from an international expert panel, opportunities. Blood. 2009 Aug 06;114(6):1150-7.
on behalf of the European LeukemiaNet. Blood. 2009
Jan 21;115(3):453-74. 56. Pearce DJ, Taussig D, Zibara K, Smith LL, Ridler
CM, Preudhomme C, et al. AML engraftment in the
42. Shipley JL, Butera JN. Acute myelogenous leukemia. NOD/SCID assay reflects the outcome of AML:
Exp Hematol. 2009 Jun;37(6):649-58. implications for our understanding of the
heterogeneity of AML. Blood. 2006 Feb
43. Estey E, Dohner H. Acute myeloid leukaemia. Lancet. 1;107(3):1166-73.
2006 Nov 25;368(9550):1894-907.
57. Cheung AM, Wan TS, Leung JC, Chan LY, Huang H,
44. Tallman MS. New agents for the treatment of acute Kwong YL, et al. Aldehyde dehydrogenase activity in
myeloid leukemia. Best Pract Res Clin Haematol. leukemic blasts defines a subgroup of acute myeloid
2006;19(2):311-20. leukemia with adverse prognosis and superior
NOD/SCID engrafting potential. Leukemia. 2007
45. Taussig DC, Miraki-Moud F, Anjos-Afonso F, Pearce Jul;21(7):1423-30.
DJ, Allen K, Ridler C, et al. Anti-CD38 antibody-
mediated clearance of human repopulating cells masks 58. van Rhenen A, Feller N, Kelder A, Westra AH,
the heterogeneity of leukemia-initiating cells. Blood. Rombouts E, Zweegman S, et al. High stem cell
2008;112(3):568-75. frequency in acute myeloid leukemia at diagnosis
predicts high minimal residual disease and poor
46. Taussig DC, Vargaftig J, Miraki-Moud F, Griessinger survival. Clin Cancer Res. 2005 Sep 15;11(18):6520-
E, Sharrock K, Luke T, et al. Leukemia-initiating cells 7.
from some acute myeloid leukemia patients with
mutated nucleophosmin reside in the CD34(-) 59. Terwijn M, Feller N, van Rhenen A, Kelder A, Westra
fraction. Blood. 2010;115(10):1976-84. G, Zweegman S, et al. Interleukin-2 receptor alpha-
chain (CD25) expression on leukaemic blasts is
47. Risueno RM, Campbell CJ, Dingwall S, Levadoux- predictive for outcome and level of residual disease in
Martin M, Leber B, Xenocostas A, et al. Identification AML. Eur J Cancer. 2009 Jun;45(9):1692-9.
of T-lymphocytic leukemia-initiating stem cells
residing in a small subset of patients with acute 60. Ran D, Schubert M, Pietsch L, Taubert I, Wuchter P,
myeloid leukemic disease. Blood. 2011 Jun Eckstein V, et al. Aldehyde dehydrogenase activity
30;117(26):7112-20. among primary leukemia cells is associated with stem
@Real Academia Nacional de Farmacia. Spain 161
